Skip to content

13F-HR filed by Fairmount Funds Management LLC

Fairmount Funds Management LLC filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-14, with 17 holding rows worth $1,111,423,463.

Accession
0001104659-25-112427
Filed
2025-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2025

A holdings report, 17 entries on the cover page, a total value of $1,111,423,463 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,111,423,463 with VALUE read as dollars as filed, 13F file number 028-19908. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
DIANTHUS THERAPEUTICS INC252828108COM3,307,191$130,137,966dollars as filed
COGENT BIOSCIENCES INC19240Q201COM9,003,418$129,289,082dollars as filed
AXSOME THERAPEUTICS INC. COM05464T104Stock815,176$99,003,125dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock2,048,647$81,392,745dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock3,711,444$75,973,259dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM3,459,913$74,664,923dollars as filed
ORUKA THERAPEUTICS INC COM687604108Stock3,705,262$71,252,188dollars as filed
KINIKSA PHARMACEUTICALS INTL P ORD SHS CL AG52694109Stock1,772,839$68,839,338dollars as filed
SCHOLAR ROCK HLDG CORP80706P103COM1,824,031$67,926,914dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW4,018,101$67,343,373dollars as filed
NUVALENT INC COM670703107Stock727,563$62,919,648dollars as filed
ABIVAX SA-00370M103SPONSORED ADS713,434$60,570,547dollars as filed
ZENAS BIOPHARMA INC COM98937L105Stock1,892,806$42,020,293dollars as filed
JADE BIOSCIENCES INC008064206COM NEW3,220,368$27,791,776dollars as filed
ASTRIA THERAPEUTICS INC COM04635X102Stock3,554,129$25,874,059dollars as filed
CRESCENT BIOPHARMA INCG2545C104COMMON STOCK1,387,866$16,501,727dollars as filed
INHIBIKASE THERAPEUTICS INC45719W205COMMON STOCK6,125,000$9,922,500dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-25-112427this filing2025-11-14acceptance time not in the bulk data set